Skip to main content
. 2021 Oct 9;55(3):302–310. doi: 10.1111/apt.16619

FIGURE 2.

FIGURE 2

Most frequently reported AEs based on MedDRA Preferred Terms (reporting proportion ≥2%): (A) tofacitinib overall, (B) tofacitinib immediate‐release formulation and (C) tofacitinib extended‐release formulation. The percentage was calculated by dividing the number of cases per Preferred Term by the total number of cases. AE, adverse event; MedDRA, Medical Dictionary for Regulatory Activities